MSI-L/dMMR	Small Intestinal Carcinoma	MSI-L/dMMR	Small Intestinal Carcinoma	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2	dostarlimab-gxly Sensitive: A2 - Guideline dostarlimab-gxly Sensitive : A2
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	MSI-L/dMMR	Pancreatic Ductal Adenocarcinoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
MSI-L/dMMR	Colorectal Cancer	MSI-L/dMMR	Colorectal Cancer	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3	camrelizumab + SHR7390 Sensitive: C3 – Early Trials camrelizumab + SHR7390 Sensitive : C3
MSI-L/dMMR	Penile Cancer	MSI-L/dMMR	Penile Cancer	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4	sintilimab Sensitive: C4 – Case Studies sintilimab Sensitive : C4

MSI-L/dMMR

Associations